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Abstract 
We report peri- and post-operative management of 
haemostasis in a 11-year old girl with Glanzmann 
Thrombasthenia (GT) who had feminizing genitoplasty for 
genital ambiguity due to Congenital Adrenal Hyperplasia 
(CAH-21 Hydroxylase deficiency). A blend of Glanzmann 
Thrombasthenia (GT) and DSD 46XX due to CAH is not 
reported in literature. Surgery particularly genitourinary 
reconstruction in patients with GT is challenging due to 
risk of intra and post-operative bleeding. Haemostasis can 
successfully be achieved with platelet transfusions, 
antifibrinolytic (Tranexamic acid) and judicious use of 
recombinant factor VIIa (rFVIIa) even in a resource limited 
setting. 
Keywords: Inherited Platelet disorders, Feminizing 
Genitoplasty, Disorders of Sexual Differentiation (DSD), 
Urogenital Sinus, Glanzmann's Thrombasthenia, 
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Introduction 
Glanzmann's Thrombasthenia (GT) is a rare autosomal 
recessive disorder of platelet aggregation due to 
qualitative/quantitative defect of platelet membrane 
glycoproteins (IIb/IIIb). Reported incidence is 1: 1000,000 
people worldwide.1,2 GT may be frequent in South-East Asia 
where consanguinity is common.3 In a series of 211 patients 
of Autosomal recessive inherited bleeding disorders 
(ARBDs) from Pakistan, 9.6% patients had GT.4 Clinical 
manifestation includes easy bruising, tendency to bleed 
from muco-cutaneous surfaces e.g. epistaxis (bleeding from 
the nose), menorrhagia( abnormally heavy bleeding at 
menstruation), and bleeding after trauma or surgery. 
In literature reports of children having GT undergoing 
minor procedures (e.g. dental extraction, herniorrhaphy) 
are common however, major surgical procedures 
particularly the genitourinary reconstructions are 
sparingly reported.5-7 In this report we share the 
experience of feminizing genitoplasty in a young girl with 
DSD 46XX due to CAH (Congenital Adrenal Hyperplasia-
21 Hydroxylase deficiency), a rare autosomal recessive 
disorder (Incidence, 1: 15,000) who also had GT. We 
believe that blend of these two autosomal recessive 
disorders is rare and is not reported in literature before. 
Case Report 
The patient was born to consanguineous parents. The 
mother was known to have Glanzmann's Thrombasthenia 
(GT) and delivered normally under the cover of platelet 
transfusions. Examination in nursery revealed ambiguous 
genitalia (enlarged clitoris, fused labio-scrotal folds and a 
single perineal opening. After the investigations which 
include serum electrolytes,17-hydroxyprogesteron, 
Ultrasound Pelvis, karyotype and Genitogram, she was 
diagnosed CAH-21-hydrooxylase deficiency and was 
categorized as DSD 46 XX. Steroid replacement 
(hydrocortisone and Florinef) was initiated. At 4.5 years she 
was diagnosed GT; after an episode of intractable epistaxis. 
Three further episodes of epistaxis were successfully 
managed by platelet transfusions and local measures. She 
was referred in June 2018 to Paediatric Surgery service at 
the Aga Khan University Hospital, Karachi (AKUH.K), 
Pakistan; at 11-years of age for feminizing genitoplasty. 
Laboratory tests revealed Haemoglobin 12.5gm/dl, 
Hematocrit 34%, WBC count 8 X 109/L, platelets 253 X 
109/L, prothrombin time (PT) :11 seconds, and activated 
partial thromboplastin time: 33 seconds. Bleeding time was 
> 14 minutes and platelet aggregation with collagen, 
adenosine diphosphate (ADP) and epinephrine was absent. 
The patient was admitted electively for the reconstructive 
surgery and co-managed with Paediatric Haematology 
and Endocrinology. One hour prior to the procedure she 
received stress dose (3 times the maintenance dose) of 
hydrocortisone, 6 units of platelets concentrate and 
tranexamic acid (10mg/kg).  
The technical details of Feminizing genitoplasty (flap 
Vaginoplasty, nerve-sparing clitoroplasty and labioplasty) 
are reported in literature.8 Cystoscopy was the initial 
procedure which revealed the length of the common 
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urogenital sinus (UG) to be 3.0 cm. The procedure continued 
for 3.15 hours. Excessive bleeding (>350 ml) was 
encountered particularly during dissection of UG and 
clitoroplasty. However, bleeding reduced (<50ml) 
remarkably after a bolus of recombinant factor VIIa (rFVIIa-
Novo-sevenR), 90ug/kg. Additional dose of rFVIIa were 
administered in recovery room and at time of dressing 
change and removal of vaginal pack on 3rd postoperative 
day. Tranexamic acid (10mg/kg) 3 times a day was 
continued, and she received 6 units of platelets concentrate 
twice daily for 7 days and once daily for the next 5 days. The 
patient recovered well and was discharged from the hospital 
on the 12th post-operative day. She did not experience any 
adverse effects of rFVIIa treatment or further oozing from the 
wound during hospitalization and on 8-week follow-up. 
Discussion 
Both GT and CAH are autosomal recessive inherited disorders 
and caused by mutation of genes (TGA2B/ITGB3 and 
CYP21A2) located on Chromosome 17 and 6 respectively. 
Mechanism of presence of these rare disorders in one patient 
is unknown and is not reported in literature.  Perhaps it can be 
explained by uniparental disomy (maternal or parental) i.e. 
inheritance by offspring of two copies of a homologous 
chromosome from one parent and none from the other. 
Surgical procedures in patients with GT are challenging due 
to increased risk intra- and post-operative bleeding and 
haematoma formation. In a series of 112 GT; 77% patients 
required blood transfusion.1 Prophylactic or therapeutic 
platelet transfusions preferably from single donor and/or 
HLA compatible along with local and general measures e.g. 
desmopressin, fibrin glue, and antifibrinolytics (e.g. 
Tranexamic acid) are usually utilized to manage bleeding 
episodes and to support surgical interventions in GT 
patients.2,9,10 However, immunity to glycoproteins IIb-IIIa 
and/or HLA may develop and render the platelet 
transfusions ineffective. Moreover, blood products carry 
risks e.g. infection, allergic reaction etc., and preferred HLA 
compatible platelets and single donor platelets may not be 
readily available. Recombinant activated factor VIIa (rFVIIa, 
NovoSevenR, Novo Nordisk A/S, Begs-vaerd, Denmark) is 
currently used as an alternative or adjuvant to platelet 
transfusions to reduce bleeding during surgical and invasive 
interventions in patients with disorders of platelet 
dysfunctions. e.g. Bernard-Soulier syndrome and GT.2,11 
None of the currently available treatment protocols are 
supported by tangible evidence. In the reported patient 
haemostasis was achieved through platelet transfusions and 
antifibrinolytics (tranexamic acid) and restricted use of rFVIIa 
as the cost of one dose of rFVIIa is US$ 560.00 in Pakistan 
where per capita income is around US$ 5500. It was effective 
in controlling intra and post-operative bleeding episodes.  
The exact mechanism of rFVIIa as haemostatic agent is 
not known. It is reported to bind activated platelets and 
boost local thrombin generation and adhesion of GP 
IIb/IIIa deficient platelets. As Fibrin is an active participant 
in platelet aggregation; antifibrinolytics such as 
tranexamic acid may have a role in management.2 
In conclusion, surgical procedures particularly genitourinary 
reconstructions in patients with GT can be carried out safely by 
careful planning and coordination between haematologist 
and the surgeon. rFVIIa is effective as an adjuvant to platelet 
transfusions; in reducing bleeding. The reported approach 
may also be applicable in children and adolescents with GT 
having minor, major surgical and obstetric procedures. 
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